A new electro-treatment flow cell design is proposed. This flow cell will be cable of performing electroporation, electrofusion, and electroinsertion. These processes can be used for therapeutic modification of erythrocytes and other types of cells. The proposed flow cell will provide many advantages including: 1) control of the orientation of asymmetric cells within flowing systems: 2) potential for increased electroporation efficiencies for asymmetric cells such as erythrocytes; 3) separation of cells from the electroporation electrodes; 4) simple maintenance of cell sterility without the use of sterile electrodes; 5) the ability to electro-treat a wide variety of cell types; and 6) easy scale-up for the preparation of large quantities of modified cells.

Proposed Commercial Applications

Using RBCs and other cell types as carriers of exogenous, agents holds great therapeutic potential. There is a need to develop processes for preparing large quantities of these drug delivery agents.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43HL059013-01A1
Application #
2540415
Study Section
Special Emphasis Panel (ZRG7-SSS-X (80))
Program Officer
Reynolds, Craig W
Project Start
1998-01-10
Project End
1999-04-30
Budget Start
1998-01-10
Budget End
1999-04-30
Support Year
1
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Symbiotech, Inc.
Department
Type
DUNS #
City
Wallingford
State
CT
Country
United States
Zip Code
06492